In phase I-III trials, epacadostat showed promising results in combination with various checkpoint inhibitors, including durvalumab (anti-PD-L1), pembrolizumab (anti-PD-1), and ipilimumab (anti-CTLA-4), in different cancer types (252). Here, CD274 is linked to cancer.